320 related articles for article (PubMed ID: 37794101)
1. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
Cross NCP; Ernst T; Branford S; Cayuela JM; Deininger M; Fabarius A; Kim DDH; Machova Polakova K; Radich JP; Hehlmann R; Hochhaus A; Apperley JF; Soverini S
Leukemia; 2023 Nov; 37(11):2150-2167. PubMed ID: 37794101
[TBL] [Abstract][Full Text] [Related]
2. Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?
Yilmaz U; Eskazan AE
Expert Rev Hematol; 2020 Oct; 13(10):1035-1038. PubMed ID: 32814447
[No Abstract] [Full Text] [Related]
3. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A; Baccarani M; Silver RT; Schiffer C; Apperley JF; Cervantes F; Clark RE; Cortes JE; Deininger MW; Guilhot F; Hjorth-Hansen H; Hughes TP; Janssen JJWM; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Mayer J; Nicolini F; Niederwieser D; Pane F; Radich JP; Rea D; Richter J; Rosti G; Rousselot P; Saglio G; Saußele S; Soverini S; Steegmann JL; Turkina A; Zaritskey A; Hehlmann R
Leukemia; 2020 Apr; 34(4):966-984. PubMed ID: 32127639
[TBL] [Abstract][Full Text] [Related]
4. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
Rea D; Mahon FX
Br J Haematol; 2018 Jan; 180(1):24-32. PubMed ID: 29048128
[TBL] [Abstract][Full Text] [Related]
5. Best Practices in Chronic Myeloid Leukemia Monitoring and Management.
Soverini S; De Benedittis C; Mancini M; Martinelli G
Oncologist; 2016 May; 21(5):626-33. PubMed ID: 27032870
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
Soverini S; Hochhaus A; Nicolini FE; Gruber F; Lange T; Saglio G; Pane F; Müller MC; Ernst T; Rosti G; Porkka K; Baccarani M; Cross NC; Martinelli G
Blood; 2011 Aug; 118(5):1208-15. PubMed ID: 21562040
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
8. Treatment and molecular monitoring update in chronic myeloid leukemia management.
Sorel N; Cayssials É; Brizard F; Chomel JC
Ann Biol Clin (Paris); 2017 Apr; 75(2):129-145. PubMed ID: 28377326
[TBL] [Abstract][Full Text] [Related]
9. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
10. Molecular
Marin AM; Wosniaki DK; Sanchuki HBS; Munhoz EC; Nardin JM; Soares GS; Espinace DC; de Holanda Farias JS; Veroneze B; Becker LF; Costa GL; Beltrame OC; de Oliveira JC; Cambri G; Zanette DL; Aoki MN
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373266
[TBL] [Abstract][Full Text] [Related]
11. Chronic Myeloid Leukemia--Prognostic Value of Mutations.
Kaleem B; Shahab S; Ahmed N; Shamsi TS
Asian Pac J Cancer Prev; 2015; 16(17):7415-23. PubMed ID: 26625737
[TBL] [Abstract][Full Text] [Related]
12. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
14. Molecular monitoring of chronic myeloid leukemia: present and future.
Yeung CC; Egan D; Radich JP
Expert Rev Mol Diagn; 2016 Oct; 16(10):1083-1091. PubMed ID: 27552202
[TBL] [Abstract][Full Text] [Related]
15. NCCN and ELN: What do the guidelines tell us?
Sweet K; Pinilla-Ibarz J
Best Pract Res Clin Haematol; 2016 Sep; 29(3):264-270. PubMed ID: 27839567
[TBL] [Abstract][Full Text] [Related]
16. Current trends in molecular diagnostics of chronic myeloid leukemia.
Vinhas R; Cordeiro M; Pedrosa P; Fernandes AR; Baptista PV
Leuk Lymphoma; 2017 Aug; 58(8):1791-1804. PubMed ID: 27919203
[TBL] [Abstract][Full Text] [Related]
17. A review of the European LeukemiaNet recommendations for the management of CML.
Baccarani M; Castagnetti F; Gugliotta G; Rosti G
Ann Hematol; 2015 Apr; 94 Suppl 2():S141-7. PubMed ID: 25814080
[TBL] [Abstract][Full Text] [Related]
18. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Guilhot J; Baccarani M; Clark RE; Cervantes F; Guilhot F; Hochhaus A; Kulikov S; Mayer J; Petzer AL; Rosti G; Rousselot P; Saglio G; Saussele S; Simonsson B; Steegmann JL; Zaritskey A; Hehlmann R
Blood; 2012 Jun; 119(25):5963-71. PubMed ID: 22508936
[TBL] [Abstract][Full Text] [Related]
19. Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.
Lu X; Song X; Ye Y; Liu X; Zhou Y; Zhang L; Wang J; Ying B; Wang L
Mol Biol Rep; 2011 Jun; 38(5):3101-5. PubMed ID: 20127176
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders.
Ross DM; Hughes TP
Pathology; 2008 Apr; 40(3):231-46. PubMed ID: 18428043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
